Skip to content
Review

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Aug 2026 · Current Pharmacogenomics and Personalized Medicine · Vol 23 · 0 citations

TL;DR

Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of multi-target therapy will improve therapeutic efficacy in the treatment of AD.

Abstract

Alzheimer’s Disease (AD) is a neurodegenerative disorder with progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress, and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dysfunction. However, the current pharmacological treatment of AD with cholinesterase inhibitors and NMDA receptor antagonists provides only symptomatic relief and cannot prevent the progression of the disease. This review article discusses the recent developments in neuropharmacology in the treatment of AD with a focus on the discovery of novel therapeutic targets and innovative therapeutic strategies with multi-target pharmacology involving protein–protein interaction inhibitors, allosteric modulators, selective enzyme inhibitors, and proteolysistargeting chimeras (PROTACs), and the discovery of novel drug delivery systems to overcome the blood–brain barrier. Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes. Dual inhibitors of tau hyperphosphorylation and Aβ aggregation have been shown to improve therapeutic efficacy, while modulation of neurotrophic signaling pathways, including BDNF, has been shown to possess neuroprotective effects. Moreover, improved drug delivery systems across the BBB will enhance drug bioavailability, thereby increasing therapeutic efficiency. Despite the promising preclinical data, there are several challenges in translating these therapeutic interventions into clinical success in AD treatment due to the complexity of the disease, delayed diagnosis, and lack of predictive markers. The incorporation of early diagnostic biomarkers in conjunction with the use of multi-target therapy will improve therapeutic efficacy in the treatment of AD. Neuropharmacological approaches, where various mechanisms of pathology are targeted, hold promise for developing disease-modifying treatments for AD. Further research in this area, incorporating innovative drug development techniques, drug delivery systems, and early intervention techniques, is crucial for better patient outcomes and slower disease progression.

View source

Similar papers

Review Open access Oct 2026

Recent advances of GPR40 agonists as potential anti-Alzheimer's agents.

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...

Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al. · 0 citations
Open access Oct 2026

"Pharmacological Modulation of Neuroinflammation in Alzheimer's Disease: Current Advances, Emerging Therapeutic Targets, and Future Perspectives"

The gradual degeneration of brain cells, known as synapses and neurones, is the main cause of memory loss and cognitive dysfunction in Alzheimer's disease (AD), a neurodegenerative disorder. Chronic neuroinflammation is an important factor in the development and advancement of the illness, with characteristic pathologi...

Vaishnavi Vijay, Patil, V. Patil et al. · 0 citations
Review Open access Nov 2026

Biochemical mechanisms of acetylcholinesterase in Alzheimer’s disease pathogenesis and future therapeutic strategies

Alzheimer’s disease is a major neurodegenerative disorder in which beta-amyloid (Aβ) proteins, tau pathology, neuroinflammation, and dysfunction of the cholinergic system interact to cause cognitive decline. Although acetylcholinesterase (AChE) has traditionally been viewed as the enzyme responsible for terminating cho...

Luma Dali, Aws Z. Abdulmajeed, Sumood N. A. Al-Hadithy et al. · 0 citations
Review Open access Oct 2026

Emerging and Repurposed Immune System Modulators for Alzheimer’s Disease

Abstract Alzheimer’s disease (AD) remains an incurable neurodegenerative condition to date. Pathologically, the hallmarks of AD are (i) extracellular senile plaques mainly composed of amyloid beta peptides (Aβ), (ii) intracellular neurofibrillary tangles comprised of abnormally folded and hyperphosphorylated tau protei...

Boris Decourt, Katia Azarfar, E. Reyna et al. · 0 citations
Review Oct 2026

Current development of therapeutic strategies for Alzheimer's disease.

Alzheimer's disease is an increasingly prevalent neurodegenerative cause of dementia. The prevailing model begins with neuronal deposits of beta-amyloid (Aβ42) (phase I), followed by intra-neuronal fibrillary tangles of p-tau (phase II) that recruit numerous effector pathways (phase III) leading to neuronal damage, syn...

E. Goetzl · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.